SIGA wins $500 million contract to produce smallpox antiviral

SIGA has received a $500 contract -- the contract will be worth as much as $2.8 billion if the government exercises all of its options -- to produce the first specialized treatment for smallpox bioterror attacks and related infections; before the company can begin work, it must fend off a legal challenge from Chimerix, Inc., an unsuccessful bidder for the contract; Chimerix claims SIGA misrepresented itself as a small business in order to win this small-business set-aside